This study is testing a new drug called redasemtide for adults who had a type of stroke called an acute ischemic stroke (AIS). AIS happens when a blood clot blocks blood flow to the brain. The study wants to see if redasemtide is safe and helpful for these patients.

To join the study, participants must start treatment within 25 hours of their stroke and have specific scores on a test called the NIHSS, which measures stroke severity. Participants should also be stable, meaning their condition isn't changing quickly. They can't join if they have other serious brain or heart issues, or if they've had certain treatments or allergies that could interfere with the study.

• Study Length: Participants will need to commit to the study timeline and follow-up visits.
• Eligibility: Specific criteria must be met to participate, including health and medical history checks.
• Risks and Benefits: The study will monitor safety, but there might be unknown risks with the new treatment.

Participation is voluntary, and potential participants should carefully consider the requirements and risks before deciding.